NasdaqGS:AMRXPharmaceuticals
A Look at Amneal Pharmaceuticals (AMRX) Valuation After Upgraded 2025 Guidance and Strong Biosimilar Progress
Amneal Pharmaceuticals (AMRX) is making headlines after revising its full-year 2025 guidance upward, a move that quickly pushed the stock to a new 52-week high. With management showing confidence in sustained revenue and earnings growth, backed by encouraging quarterly results and progress on two Denosumab biosimilars under FDA review, investors are once again asking if now is the time to reconsider the stock. This guidance bump, combined with executive-level insider activity and a recently...